-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O3.3 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies

Symposia: Multiple Myeloma: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Research, Clinical trials, Combination therapy, Clinical Practice (Health Services and Quality), Translational Research, CHIP, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
Phoebe Joy Ho, MBBS, Royal Prince Alfred Hospital and University of Sydney and Rahul Banerjee, MD, FACP, University of California, San Francisco
Disclosures:
Ho: Novartis: Other: Research support on medical writing. Banerjee: Adaptive; BMS; Caribou Biosciences; Genentech; GSK; JNJ / Janssen; Karyopharm; Legend Biotech; Pfizer; Sanofi; SparkCures: Consultancy; Abbvie; JNJ; Novartis; Pack Health; Prothena; Sanofi: Research Funding.

This oral session is dedicated to optimizing outcomes for patients receiving anti-BCMA CAR-T and bispecific antibody (BsAb) T cell engager therapies. The first presentation examines how prior high-dose melphalan with autologous stem cell transplantation (HDM/ASCT) can adversely affect progression-free survival (PFS) in patients undergoing BCMA-directed CAR T-cell therapy, adding to the ongoing discussion about treatment sequencing in the CAR-T era. The second and third talks address strategies to mitigate complications associated with T cell redirection therapies, such as prolonged cytopenias and infections, which are clinically significant. Collectively, these presentations aim to enhance patient outcomes in the context of anti-BCMA T cell redirection therapies.
2:00 PM

Jennifer H Cooperrider, MD1, Diren Arda Arda Karaoglu, MD2,3, Tadeusz Kubicki4*, Ken Jiang5*, Ella Postich1*, Kathryn Kimi Shimamoto2*, Olivia Arnold6*, Aubrianna Ramsland5*, Anna Pula5*, Jommel Macaraeg, BS7*, Andrzej J Jakubowiak, MD, PhD4, Benjamin A Derman, MD4 and Caner Saygin, MD1

1Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
2Section of Hematology/Oncology, The University of Chicago, Chicago, IL, Chicago, IL
3Contributed equally, Chicago
4Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL
5University of Chicago, Chicago, IL
6University of Chicago, Chicago
7The University of Chicago, Chicago, IL

2:15 PM

Kritika Yadav, MD1*, Tanvi H. Patel, MD2*, Ramya Bachu, MD2*, Jean Esselmann, RN3*, Lisa E Rein, ScM4*, Aniko Szabo, PhD5*, Abhishek Janardan, MD6*, Evanka Annyapu, BS7*, Catherine E. Skoog, PA8*, Areyl Goff, MSN, RN, NP8*, Othman S Akhtar, MD9, Samer Al Hadidi, MD, MSc2, Sharmilan Thanendrarajan, MD2, Maurizio Zangari, MD2, Nirav N. Shah, MD10, Frits van Rhee, MD, PhD2, Mehdi Hamadani, MD11, Binod Dhakal, MBBS8, Anita D'Souza, MD12, Meera Mohan, MD8 and Carolina Schinke, MD2

1Medical College of Wisonsin, Milwaukee, WI
2Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
3BMT and Cellular Therapy Program, Froedtert & The Medical College of Wisconsin, Milwaukee
4Department of Statistics, Medical College of Wisconsin, Milwaukee, WI
5Medical College of Wisconsin, Milwaukee, WI
6Department of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
7Department of Medicine, Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
8Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
9CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
10Medical College of Wisconsin, Brookfield, WI
11Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
12Division of Hematology/Oncology, Department of Medicine, Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, WI

2:30 PM

Craig C. Hofmeister, MD1, Vikas A. Gupta, MD PhD1, Jonathan L. Kaufman, MD1, Ajay K. Nooka, MD, MPH2, Nisha S. Joseph, MD1, Sagar Lonial, MD1* and Madhav V. Dhodapkar, MD PhD1

1Winship Cancer Institute of Emory University, Atlanta, GA
2Winship Cancer Institute of Emory University, Atlanta

2:45 PM

Heloise Cheruvalath1, Anna Clennon2*, Asis Shrestha, MD3*, Aniko Szabo, PhD1*, Vineel Bhatlapenumarthi, MD4*, Anannya Patwari, MD1*, Metodi Balev5*, Divaya Bhutani, MD6, Sharmilan Thanendrarajan, MD7, Binod Dhakal, MBBS8, Maurizio Zangari, MD7, Anup Kumar Trikannad, MD3, Sruthi Vellanki, MD3*, Samer Al Hadidi, MD, MSc9, Suzanne Lentzsch, MD, PhD10, Frits van Rhee, MD, PhD3, Mansi R. Shah, MD11, Aishee Bag, MD12*, Anita D'Souza, MD13, Rajshekhar Chakraborty, MD6, Nishi Shah, MBBS, MPH14, Carolina Schinke, MD7 and Meera Mohan, MD15

1Medical College of Wisconsin, Milwaukee, WI
2Aurora St. Lukes Hospital, Milwaukee
3University of Arkansas for Medical Sciences, Little Rock, AR
4Department of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
5Columbia University Irving Medical Center, New York, NY
6Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
7Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
8Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
9UAMS, Little Rock, AR
10Division of Hematology & Oncology, Columbia University Medical Center, New York, NY
11Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
12Rutgers Cancer Institute of New Jersey, New Jersey
13Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
14Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
15Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

3:00 PM

Smith Giri, MD, MHS1*, Binod Dhakal, MBBS2, Natalie Callander, MD3, Eva Medvedova, MD4*, Kelly Godby1*, Susan Bal, MD1, Gayathri Ravi, MD1, Saurabh Chhabra, MD5, Rebecca W. Silbermann6 and Luciano J. Costa, MD, PhD7

1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
2Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3University of Wisconsin, Carbone Cancer Center, Madison, WI
4Knight Cancer Institute, Oregon Health & Science University, Portland, OR
5Division of Hematology, Mayo Clinic, Phoenix, AZ
6Oregon Health and Science University, Portland, OR
7Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL

3:15 PM

Joao Tadeu Damian Souto Filho, MD, PhD1,2, Lucas Oliveira Cantadori, MD, PhD3*, Edvan De Queiroz Crusoe, MD, PhD, MSc4,5, Vania Hungria, MD, PhD6 and Angelo Maiolino, MD, PhD7,8*

1Faculdade de Medicina de Campos, Campos dos Goytacazes, RJ, Brazil
2Instituto Federal de Educação, Ciência e Tecnologia Fluminense, Campos dos Goytacazes, RJ, Brazil
3Hospital das Clínicas, Universidade Estadual Paulista, UNESP, Botucatu, São Paulo, Brazil
4Instituto D'Or de Pesquisa, IDOR Oncologia, Hospital Sao Rafael, Salvador, Bahia, Brazil
5Rede D'or Oncologia, Salvador, Bahia, Brazil
6Clinica São Germano, São Paulo, Brazil
7Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil
8Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, RJ, Brazil

*signifies non-member of ASH